NCT03903796View on ClinicalTrials.gov

Study of the Efficacy and Safety of HS-10234 in Patients With Chronic Hepatitis B Virus Infection

PHASE3CompletedINTERVENTIONAL
Enrollment

963

Participants

Timeline

Start Date

August 16, 2018

Primary Completion Date

May 31, 2020

Study Completion Date

June 7, 2024

Conditions
Chronic HBV Infection
Interventions
DRUG

HS-10234

Drug: HS-10234 HS-10234 25mg will administer orally once daily Drug: TDF placebo TDF placebo 300mg will administer orally once daily

DRUG

TDF

Drug: TDF TDF 300mg will administer orally once daily Drug: HS-10234 placebo HS-10234 placebo 25mg will administer orally once daily

Trial Locations (1)

Unknown

The First Hospital of Jilin University, Changchun

Sponsors
All Listed Sponsors
lead

Jiangsu Hansoh Pharmaceutical Co., Ltd.

INDUSTRY